Genezen Expands Presence Through Acquisition of uniQure's Gene Therapy Operations

Monday, 1 July 2024, 11:15
Genezen has successfully acquired uniQure's gene therapy operations in Lexington. This acquisition is accompanied by strategic supply agreements and funding from Ampersand Capital Partners, paving the way for greater advancements in the gene therapy sector. The collaboration between Genezen and uniQure is poised to drive innovation and propel the companies to the forefront of gene therapy research.
LivaRava Finance Meta Image
Genezen Expands Presence Through Acquisition of uniQure's Gene Therapy Operations

Genezen Acquires uniQure's Gene Therapy Operations

Genezen has acquired uniQure's gene therapy operations in Lexington, marking a significant development in the gene therapy sector.

Strategic Partnerships and Funding

  • Ampersand Capital Partners: Providing crucial funding support for the acquisition.
  • Supply Agreements: Forming strategic partnerships to enhance operations.

This collaboration is set to drive innovation and progress in gene therapy research, positioning Genezen and uniQure at the forefront of the industry.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe